Is it safe?
Can BMRN take a bad year?
BioMarin Pharmaceutical Inc. holds $722M more cash than debt, so a bad year is a question about profits, not about lenders.
$722M
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 5.55
Altman Z-score · safe zone, above 3
- Interest cover
- 17.9×
Interest cover · operating profit covers the interest bill several times over
Details›
- Total debtQ1 2026
- $1.50B
- Cash and short-term investments
- $2.22B
- Net cash
- $722M
- EBITDA, trailing twelve months
- $373M
- Operating profit, trailing twelve months
- $315M
- Debt / equity
- 0.24×
- Total debt / EBITDA
- 4.02×
- Annualised volatilitytwo years of daily moves
- 36%
- Worst drawdown on file
- −62%
- Below its 52-week high
- −6.6%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.